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A B S T R A C T   
Purpose: The aim of this study was to quantify the prevalence of Fear of Cancer Recurrence (FCR) in patients with 
a prior haematology malignancy surviving more than one year post allogeneic haematopoietic stem cell trans-
plantation (HSCT), and to identify the demographic, medical and psychological factors associated with FCR 
occurrence. 
Method: Participants were adult allogeneic HSCT recipients who had undergone the procedure for acute 
leukaemia or other haematological malignancy between the years 2000–2012 in Sydney, Australia. They 
completed a purpose designed survey and six other validated instruments which assessed FCR, psychological 
functioning, quality of life, demographic, social and clinical variables. 
Results: Of the 364 respondents, approximately 11% of the sample lived with severe FCR while only 5% of 
subjects reported having no FCR. Variables significantly associated with higher FCR included unemployment, a 
shorter time (years) post-transplant, not attending to health screening (PAP smear), a secondary diagnosis of skin 
cancer, younger age, referral to a psychiatrist and taking psychotropic medication. Higher psychological distress 
(depression, anxiety, stress) and lower quality of life made a significant contribution to the prediction of FCR. 
Conclusions: Post HSCT follow-up care should include an assessment and discussion regarding FCR to balance 
both realistic and unrealistic cancer recurrence risks. Managing FCR is one of the most ubiquitous unmet needs of 
survivors of haematological disease and it is important that HSCT nurses are both aware of the fear, and are 
equipped with knowledge on how to help patients navigate it with realistic expectations.   
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1. Introduction 
Allogeneic haematopoietic stem cell transplantation (HSCT) is used 
worldwide to treat adults and children with a range of life-threatening 
malignant and non-malignant disorders including leukaemia and other 
haematological malignancies, immunodeficiency syndromes, haemo-
globinopathies and metabolic disorders (Majhail et al., 2015). In recent 
years improvements in donor selection, chemo-radiotherapy condi-
tioning and supportive care have meant that an increasing number of 
patients will become long-term survivors of allogeneic HSCT (Kliman 
et al., 2020). Many, however, experience one or more chronic health 
conditions post-HSCT and many live with the possibility that their 
original disease will recur (Barrett and Battiwalla, 2010; Mohty and 
Mohty, 2011). Relapse remains the most frequent cause of treatment 
failure and mortality, and it is particularly common in patients who have 
undergone HSCT for high risk haematological malignancies or relapsed 
disease. Primary disease is responsible for 21 and 59% of deaths in the 
first 100 days, and after the first 100 days respectively post allogeneic 
HSCT (depending on the primary disease and donor type) (D’Souza 
et al., 2020). Consequently, many HSCT survivors live with the anxiety 
and fear associated with disease recurrence (Bacigalupo et al., 2004; 
Gilroy et al., 2016; Serna et al., 2003). 
Fear, worry or concern relating to the possibility that cancer will 
come back, or progress, has been termed the Fear of Cancer Recurrence 
(FCR) and is estimated to affect between 22% and 87% of cancer sur-
vivors (Lebel et al., 2016). A number of psychological, medical, 
behavioural and socio-demographic factors have been found to predict 
its occurrence, including a diagnosis of anxiety or depression, young age 
at treatment, years since treatment, poorer quality of life (QoL), expe-
riencing adverse effects of treatment, complementary medicine use, 
educational status, gender, income, occupation and ethnicity (Simard 
and Savard, 2009; Simard et al., 2010a). Systematic reviews of FCR have 
identified younger age at transplant as a key demographic determinant 
of FCR and have found moderate evidence for a relationship between 
FCR and educational status, gender, income, occupation and ethnicity 
(Costanzo et al., 2007; Koch et al., 2013; Sarkar et al., 2014b; Thewes 
et al., 2012a). Correlations between years since treatment and medical 
side effects and FCR have also been established (Sarkar et al., 2014b; 
Thewes et al., 2012a). Interestingly, despite research demonstrating 
strong associations between anxiety, depression and FCR, it has been 
found that FCR is not related to psychotropic medication use or having 
psychiatric treatment (Koch et al., 2013; Rabin et al., 2004; Skaali et al., 
2009). Furthermore, higher FCR has been shown to be associated with 
complementary therapies use and health promoting behaviours, 
including maintaining a healthy diet, using sunscreen and attending 
regular health reviews (Egger et al., 2018). FCR has not been shown to 
be associated with behaviours that may increase the risk of cancer, 
including alcohol consumption or smoking (Hawkins et al., 2010). 
The impact of FCR appears to be profound, with studies suggesting 
that it is one of the most significant psychological challenges that cancer 
survivors face and is one of the most frequent unmet supportive care 
needs (Armes et al., 2009; Beesley et al., 2013; McDowell et al., 2010; 
Minstrell et al., 2008). While FCR has been described in patients who 
have undergone chemotherapy, surgery or radiotherapy to treat solid 
cancers, little is known about FCR following allogeneic HSCT for hae-
matological malignancy (Sarkar et al., 2014a). This represents a major 
limitation of what is known about the psychological experience of HSCT 
survivors as the majority of patients who undergo transplant have 
haematological cancers, and relapse post allogeneic HSCT is infre-
quently curable (Barrett and Battiwalla, 2010; D’Souza et al., 2020). As 
is the case with HSCT more generally, patients with cancer who undergo 
HSCT have generally exhausted most other treatment options and HSCT 
is typically undertaken because it represents the best (and often last) 
option for cure. 
The aim of this study was to determine the prevalence of FCR in 
patients with a haematological malignancy surviving more than one- 
year post allogenic HSCT and to identify the demographic, medical 
and psychological factors associated with its occurrence. It is hoped that 
the information gleaned from this study will inform the design and de-
livery of health services to survivors of allogenic HSCT, and will aid in 
the education and support of those patients and families undergoing 
transplant. This is important for HSCT Nurses as they are often the first 
line of contact between survivors and the HSCT team. 
2. Methods 
2.1. Patients and procedures 
This manuscript reports results from a larger cross-sectional survey 
study assessing the health, financial, cognitive, sexual and psychosocial 
experience of life post-transplant of allogeneic HSCT survivors (Brice 
et al., 2017; Dyer et al., 2016a, 2016b, 2018; Gifford et al., 2016). The 
study sample was selected from allogeneic transplant databases of all 
four major metropolitan hospitals in New South Wales (NSW), Australia. 
Participants were eligible if they were ≥18 years of age and had un-
dergone an allogeneic HSCT for a haematological malignancy between 
January 1, 2000 and December 31, 2012 and could read and write En-
glish. Potential participants were given the option of self-completing the 
survey or completing it with one of the researchers in a phone interview. 
All participants chose to self-complete the questionnaire. Surveys were 
given out in clinic, or sent in the mail, to eligible participants between 
October 2013–December 2013, and study close date was March 2104. 
All participants were given two months to return the survey before 
receiving a reminder phone call. After follow-up phone calls, 17 people 
explicitly declined and 125 did not return the survey. The study protocol 
was approved by the Northern Sydney Local Health District Human 
Research Ethics Committee (NSLHD Reference: 1207-217 M). 
2.2. Instruments 
Study participants completed a purpose designed questionnaire; the 
Sydney post BMT Study Survey, as well as a range of other validated in-
struments to explore their quality of life (QoL), psychological morbidity 
and health concerns post-HSCT. This include the Functional Assessment of 
Cancer Therapy – Bone Marrow Transplant (FACT-BMT Version 4) (Cella 
et al., 1993; McQuellon et al., 1997) anxiety stress and depression (The 
DASS 21) (Crawford and Henry, 2003; Dahm et al., 2013; Lovibond, 
1996), chronic GVHD (The Chronic GVHD Activity Assessment – Patient 
Self Report (Form B) (Pavletic et al., 2006) and The Lee Chronic GVHD 
Symptom Scale) (Lee et al., 2002), The Post Traumatic Growth Inventory 
Score (Morris et al., 2013; Tedeschi and Calhoun, 1996) and the Fear of 
Recurrence Scale (Greenberg et al., 1997). These surveys are described 
next. 
The Sydney Post-BMT Survey was devised by the research team in 
collaboration with health professionals involved in the care of HSCT 
patients, including haematologists, infectious disease physicians, HSCT 
nurses, HSCT psychologists, and dieticians, and discussions with trans-
plant survivors attending HSCT clinics. It is a 402-question survey 
covering twenty areas including:  
1. Demographics (6 questions)  
2. Medical complications (36 questions)  
3. Referrals, tests and assessment and time (35 questions)  
4. Medications and treatments (27 questions)  
5. Oral and dental health (15 questions)  
6. Infections (17 questions)  
7. Vaccinations (30 questions)  
8. Complementary therapies (17 questions)  
9. Cancer screening (37 questions)  
10. Travel history (36 questions)  
11. Close personal contacts (6 questions)  
12. Lifestyle (10 questions) 
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13. Diet/Nutrition (19 questions)  
14. Occupation – Infection risk (11 questions)  
15. Occupation – works status and functioning (35 questions)  
16. Fertility and sexual function (41 questions)  
17. Relationships (3 questions)  
18. Preference for long term follow up care (8 questions) 
19. Social, occupational attitudes, physical and psychological con-
cerns (12 questions)  
20. The three things that have impacted you most (1 question) 
The SPBS survey used tick box responses, short answer questions and 
5-point Likert scales measuring attitudes and other factors and took 
approximately 1 h to complete. It was piloted in two HSCT clinics by six 
HSCT survivors to check for face and content validity. No changes were 
required after piloting. A copy of the survey can be found in the sup-
plementary material. 
2.2.1. Functional Assessment of Cancer Therapy – Bone Marrow 
Transplant (FACT-BMT version 4) 
The FACT-BMT is a validated questionnaire for measuring QoL in 
HSCT recipients (7). It takes three to 5 min to complete and combines 
two instruments, the FACT-G and a HSCT subscale. The FACT-G is a 
twenty eight-item self-report instrument that measures QoL in cancer 
patients (8). It consists of five subscales measuring physical, functional, 
social and emotional well-being and satisfaction with the doctor/patient 
relationship. The BMT subscale includes twelve items designed to test 
QoL in HSCT patients. The FACT-BMT plus the BMT subscale provides 
an overall QoL score. Patients rate themselves over the past seven days 
using five-step Likert scales with responses used to calculate overall QoL 
and subscale wellbeing scores. 
2.2.2. The Chronic GVHD Activity Assessment – Patient Self Report (form 
B) 
The Chronic GVHD Activity Assessment – Patient Self Report Form B 
was developed by the NIH Consensus Development Project (9). It is a 
ten-item questionnaire which asks patients to report on the severity and 
intensity (out of 10) of skin, oral, ocular and vulvovaginal symptoms as 
well as perceived global ratings of GVHD. It takes about 1 min to 
complete. 
2.2.3. The Lee Chronic GVHD Symptom Scale 
The Lee Chronic GVHD Symptom Scale is a thirty-item validated 
questionnaire for measuring symptoms of cGVHD (10). It consists of 
seven subscales measuring adverse effects of cGVHD on skin, eyes, 
mouth, lungs, nutritional status, muscles and joints, vitality and psy-
chological functioning. Patients rate themselves over the past month 
using five-step Likert scales. It takes about 2 min to complete. 
2.2.4. The Post Traumatic Growth Inventory 
The Post Traumatic Growth Inventory is a twenty one-item ques-
tionnaire which measures post traumatic growth experiences in trauma 
survivors’ lives (11). It is widely used to assess positive life changes 
following traumatic events such as cancer, HIV, rape and disasters and 
other crises (12). Statements including ‘I developed new interests’, ‘I 
know that I can handle difficult situations’ and ‘I learned a great deal 
about how wonderful people are’ expressed and the reader is asked to 
respond using a six-point Likert scale with responses ranging from, ‘I did 
not experience this change’ to ‘I experienced this change to a very great 
degree as a result of my crisis’. 
2.2.5. The DASS 21 
The Depression, anxiety and stress scale (DASS 21) is a twenty one- 
item self-report questionnaire designed to measure the severity of a 
range of symptoms common to both depression and anxiety (15). It uses 
a four-point Likert scale and each question is scored out of three for an 
overall total score out of sixty three. A higher score indicates greater 
severity of symptoms of anxiety or depression. 
2.2.6. The Fear of Recurrence Scale 
The Fear of Recurrence Scale was developed in the early 1990s by the 
authors of a study looking at. 
QoL in Leukaemia patients. It consists of five questions which mea-
sure individual’s thoughts surrounding recurrence of their disease. Each 
question is scored on a 5-point likert scale, with the total possible score 
range from 5 to 25. Higher scores indicate higher FCR; a score of ≥4 on 
any question = severe FCR (Greenberg et al., 1997). 
2.2.7. Clinical HSCT variables 
Clinical HSCT variables were also collected from the transplant da-
tabases of the participating hospitals. These data together with data on 
malignancy type, demographic and social variables, comorbidities, 
secondary cancer diagnosis, specialist medical reviews, medications, 
post-transplant screening and lifestyle factors, were assessed for their 
association with FCR. 
2.3. Statistical analysis 
Categorical responses were summarised using frequencies and per-
centages. Parametric continuous variables were summarised using 
means and standard deviations, and non-parametric variables using 
medians and interquartile ranges. The Pearson χ2 test or Fishers Exact 
tests were used for comparative analysis of dichotomous categorical 
variables. Two sample comparisons of parametric and nonparametric 
continuous data were determined using the independent t-test, and 
Wilcoxon Rank Sum tests respectively; greater than two sample com-
parisons were determined using one-way analysis of Variance (ANOVA) 
and Kruskal Wallis tests. A two-tailed p value < 0.05 was used as the 
level of statistical significance. Hierarchical regression analysis was used 
to assess predictors of FCR. Statistical analysis was performed using 
Stata software (Version 12.1). 
3. Results 
A total of 1475 allogeneic HSCT were performed in the study period 
Fig. 1. Study flowchart.  
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across four major transplant centres in Australia. Four hundred and 
forty-one HSCT survivors (66% of total eligible, 76% of those contacted) 
returned the completed survey. Of these, 364 patients had a pre- 
transplant diagnosis of a haematological malignancy (Fig. 1). Re-
spondents consisted of 250 (56.7%) males and 191 (43.3%) females with 
a median age of 54 years. A total of 86.6% identified as being of 
Australian/European ethnicity and 72.2% lived in a major city. Most 
respondents (46.3%) were between 2 and 6 years post-transplant and 
53.4% had an underlying diagnosis of acute leukaemia. Many (66.9%) 
reported being in CR1/CR2 at the time of transplant, over half (56.7%) 
had a sibling donor, 86.4% received peripheral blood stem cells and 
almost half (48.7%) received myeloablative conditioning for their BMT, 
with 28.6% receiving T-cell depletion of some form (Table 1). 
3.1. Prevalence of FCR 
Questions relating to FCR were completed by 355 of the 364 re-
spondents. The mean (standard deviation) of FCR scores for 355 cancer 
survivors was 13.22 (4.46) (Table 1). Approximately 11% of the sample 
(10.98%) lived with severe FCR and only 5% of subjects reported having 
no symptoms to suggest FCR. All other respondents scored in the mod-
erate range on the FCR Scale. 
3.2. Demographic, transplant factors and FCR 
There were no significant differences in mean FCR scores by age, 
gender, place of residence, income or ethnicity. Similarly, mean FCR 
scores did not differ significantly for level of education or income group. 
Those in full or part time employment showed significantly lower mean 
FCR scores compared to those not employed (p = 0.01). Those with an 
acute leukaemia diagnosis in first or second remission (a prognostic 
factor for cure following transplant) had FCR scores that were lower 
than those in later stages of remission, though this was not statistically 
significant. Being more years out from transplantation showed a sig-
nificant negative association with FCR, such that those in the first two 
years post-transplant had the highest FCR scores (p < 0.0001) (Table 2). 
Table 1 
Demographic, social and transplant variable of study respondents.  
Demographic and social variables Results (N = number of responses) 
Median years since transplant (IQR; range) 5 (IQR: 3, 8; range 1–14) 
Years since transplant, category (N = 441) 
<2yrs 58 (13.2%) 
2 to <6 yrs 204 (46.3%) 
6 to <10 yrs 117 (26.5%) 
10–14 yrs 62 (14.1%) 
Median age at survey, years (IQR; range) 54 (IQR: 44,62; range 19–79) 
Median age at transplant, years (IQR; 
range) 
49 (IQR: 38,56; range 17–71) 
Age groups, years (N = 441) 
19–29 30 (6.8%) 
30–39 49 (11.1%) 
40–49 83 (18.8%) 
50–59 130 (29.5%) 
60–69 127 (28.8%) 
>70 22 (5.0%) 
Gender (N = 441) 
Male 250 (56.7%) 
Female 191 (43.3%) 
Culture, ethnicity (N = 372) 
Australian/European 323 (86.8%) 
Indigenous Australian 2 (0.5%) 
Asian 30 (8.1%) 
Middle Eastern 7 (1.9%) 
Other 10 (2.7%) 
Education (N = 333) 
Some high school 53 (15.9%) 
Completed High school 79 (23.7%) 
Trade qualifications/diploma 47 (14.1%) 
Some university 24 (7.2%) 
Completed university 130 (39.0%) 
Household income, post-transplant (N = 423) 
Low income $20,000–39,999 155 (36.6%) 
Middle income $40,000–79,999 123 (29.1%) 
High income ≥$80,000 145 (34.3%) 
Demographic and social variables 
Employment status, post-transplant (N = 412) 
Full-time 131 (31.8%) 
Part-time 78 (18.9%) 
Homemaker 21 (5.1%) 
Casual 26 (6.3%) 
Unemployed 20 (4.8%) 
Unable to work, poor health 56 (13.6%) 
Retired 80 (19.4%) 
Residential location (N = 431) 
RA1 (Major city) 311 (72.2%) 
RA2 (Inner regional) 85 (19.7%) 
RA3 (Outer regional) 31 (7.2%) 
RA4 (Remote) 4 (0.9%) 
RA5 (Very remote) 0 
Relationship status (N = 434) 
Single 67 (15.4%) 
Married 311 (71.7%) 
Defacto 33 (7.6%) 
Divorced 18 (4.2%) 
Separated 5 (1.1%) 
Transplant variables 
Underlying diagnosisy (N = 423) 
AML/ALL 169/57 = 226 (53.4%) 
CML 21 (5.0%) 
CLL 19 (4.5%) 
SAA 16 (3.8%) 
NHL 79 (18.7%) 
HL 5 (1.2%) 
MM 14 (3.3%) 
MDS/myeloproliferative disorder 39 (9.2%) 
Other (unspecified) 4 (0.9%) 
Remission status (N = 405) 
CR1/CR2 271 (66.9%) 
>CR2 22 (5.4%) 
Chronic Phase 18 (4.4%) 
Accelerated Phase and blast crisis 3 (0.7%) 
Refractory 22 (5.4%) 
Partial remission 23 (5.7%)  
Table 1 (continued ) 
Demographic and social variables Results (N = number of responses) 
Other 46 (11.4%) 
Donor type (N = 439) 
Sibling 250 (56.9%) 
Haploidentical 10 (2.3%) 
Matched unrelated 158 (36.0%) 
Mismatched unrelated 21 (4.8%) 
Stem cell source (N = 441) 
Bone marrow 48 (10.9%) 
PBSCT 381 (86.4%) 
Cord 12 (2.7%) 
Conditioning (N = 439) 
Myeloablative – proportion with TBI 214 (48.7%)– TBI 101/214 =
47.2% 
Bu/Cy 79 (36.9%) 
Cy/TBI 99 (46.3%) 
Bu/Flu 28 (13.1%) 
Cy/ATGAM 5 (2.3%) 
Cy/Flu/ATGAM 1 (0.5%) 
Bu/Flu/Thymoglobulin/TBI 1 (0.5%) 
Etop/TBI 1 (0.5%) 
Reduced-intensity – proportion with TBI 225 (51.3%)– TBI 26/225 = 11.6% 
Flu/Cy 24 (10.7%) 
Flu/Cy/TBI 14 (6.2%) 
Flu/Mel 98 (43.6%) 
FLAMSA 1 (0.4%) 
Flu/BCNU/Mel/ATG 42 (18.7%) 
Flu/TBI 12 (5.3%) 
Other (unspecified) 34 (15.1%)  
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3.3. Medical co-morbidity and FCR 
Medical conditions diagnosed since transplantation that showed an 
association with increased mean FCR included skin cancer (p = 0.01), 
depression (p = 0.01) and anxiety (p = 0.003) (see Table 3). Higher 
mean FCR scores were reported in those taking antidepressants (p =
0.04), anxiolytics (p = 0.02) and sedatives (p = 0.01). Mean FCR scores 
were significantly higher for those referred to psychiatrists (p = 0.003). 
3.4. Routine cancer screening and FCR 
Potential associations between FCR and the uptake of routinely 
recommended screening for post-transplant secondary malignancies 
were explored. No mean differences in FCR were seen in those who did 
or did not attend skin checks, bowel screening, mammography (females) 
or prostate checks (males) including those who underwent these 
screening procedures either early or late post-transplant. The only sig-
nificant difference in mean FCR was in women who did not report at 
least one PAP smear since transplant. Those HSCT survivors who had not 
attended a PAP smear post HSCT reported significantly higher mean FCR 
scores (p = 0.003). This was significant for women who reported no Pap 
screening early post-transplant (p = 0.004) (Table 4). 
3.5. Lifestyle & complementary therapies and FCR 
No significant correlation was found between FCR and different 
health behaviours and lifestyle choices including cigarette smoking, 
alcohol consumption, exercise or the routine use of sunscreen, and those 
who elected to use a range of complementary therapies. (Table 5). 
3.6. Psychological variables, regression analysis and FCR 
Zero-order correlations were calculated for all variables included in 
the hierarchical multiple regression (Table 6). Full- or part-time 
employment, prescription of psychopharmacological medications and 
psychological distress all showed a significant positive correlation with 
Table 2 
Demographic, social, transplant variables and their associations with fear of 
cancer recurrence (FCR) post HSCT.  
Variables FCR Score Mean (sd) P value 
Demographic 
Gender 
Male 13.46 (4.40) 0.23 
Female 12.89 (4.52)  
Age (years) 
<54 (n = 179) 13.08 (4.64) 0.55 
≥54 (n = 176) 13.36 (4.27)  
Postcode 
City-Metro (n = 252) 13.25 (4.61) 0.74 
Regional or remote (n = 95) 13.07 (4.12)  
Ethnicity 
Caucasian/European (n = 261) 12.99 (4.52) 0.62 
Other (n = 42) 13.36 (4.52)  
Socioeconomic 
Education 
Some high school (n = 40) 13.32 (4.18) 0.98 
Completed High school (n = 60) 13.08 (4.56)  
Trade/diploma (n = 41) 12.90 (4.01)  
Some university (n = 17) 13.00 (4.17)  
Completed university (n = 112) 13.34 (4.73)  
University Education (n = 129) 13.29 (4.64) 0.72 
No University Education (n = 141) 13.10 (4.27)  
Post-transplant income 
Low income (n = 123)∧∧ 13.54 (4.37) 0.29 
Middle-High income (n = 217) 13.00 (4.57)  
Occupational status 
Full/Part time (n = 170) 12.66 (4.45) 0.01 
Other *(n = 159) 13.89 (4.39)  
Marital status 
Married or defacto (n = 283) 13.45 (4.38) 0.11 
Other **(n = 67) 12.48 (4.76)  
Transplant factors 
Pretransplant Cancer Diagnosis 
Acute Leukaemia (n = 223) 13.03 (4.74) 0.31 
Other (n = 132) 13.53 (4.28)  
Pretransplant remission status in those with AL 
CR1/2 (n = 208) 12.89 (4.25) 0.06 
Other (n = 15) 15.00 (4.31)  
Years since transplant 
<2 yrs (n = 51) 15.37 (4.49) <0.0001 
2 < 6 yrs (n = 160) 13.67 (4.22)  
6 < 10 yrs (n = 94) 11.84 (4.35)  
≥10yrs (n = 50) 12.16 (4.34)  
Conditioning 
Myeloablative (n = 175) 13.11 (4.60) 0.65 
Reduced Intensity (n = 178) 13.33 (4.35)   
Table 3 
Post transplant diagnosis, psychotropic medication and mental health referrals 
and their association with fear of cancer recurrence (FCR).  
Clinical factors FCR score Mean (sd) P value 
Thyroid Disease 
Yes (n = 15) 13.60 (4.92) 0.72 
No (n = 298) 13.18 (4.34)  
Bone Disease 
Yes (n = 104) 13.18 (4.35) 0.99 
No (n = 219) 13.22 (4.49)  
CVS risk factors 
Yes (n = 148) 13.04 (4.28) 0.81 
No(n = 181) 13.16 (4.52)  
Cataracts 
Yes (n = 100) 13.09 (4.11) 0.88 
No (n = 228) 13.17 (4.51)  
Iron Overload 
Yes (n = 100) 12.94 (4.08) 0.66 
No (n = 223) 13.17 (4.50)  
Recurrent colds 
Yes (n = 80) 13.44 (4.35) 0.43 
No (n = 242) 12.99 (4.36)  
Mouth Cancer 
Yes (n = 6) 16.33 (3.50) 0.07 
No (n = 308) 13.06 (4.41)  
Skin cancer 
Yes (n = 74) 14.25 (4.37) 0.01 
No (n = 251) 12.82 (4.49)  
Other Cancer 
Yes (n = 13) 15.07 (4.57) 0.13 
No (n = 342) 13.15 (4.44)  
Depression 
Yes (n = 74) 14.54 (4.64) 0.006 
No (n = 250) 12.91 (4.38)  
Anxiety 
Yes (n = 66) 14.65 (4.38) 0.003 
No (n = 257) 12.86 (4.40)  
cGVHD 
Yes (n = 244) 13.40 (4.43) 0.13 
No (n = 104) 12.61 (4.47)  
Medications 
Antidepressant 
Yes (n = 43) 14.49 (4.82) 0.04 
No (n = 312) 13.04 (4.39)  
Anxiolytic 
Yes (n = 23) 15.35 (4.79) 0.02 
No (n = 332) 13.07 (4.40)  
Sedation/sleeping tablets 
Yes (n = 39) 15.02 (4.60) 0.007 
No (n = 317) 12.98 (4.40)  
Mental health referral FCR Score Mean (sd) P value 
Psychologist 
Yes (n = 65) 13.89 (4.44) 0.20 
No (n = 269) 13.10 (4.47)  
Psychiatrist 
Yes (n = 26) 15.77 (5.13) 0.003 
No (n = 304) 13.05 (4.39)  
Social Worker 
Yes (n = 44) 14.29 (4.39) 0.09 
No (n = 289) 13.07 (4.42)   
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FCR while the number of years since transplant and QoL demonstrated a 
significant negative correlation with FCR. The two key variables of in-
terest, psychological distress (depression, anxiety and stress), and QoL 
were significantly negatively correlated with one another (Table 6). 
Hierarchical regression was used to test the degree to which age, full- 
or part-time employment, psychopharmacological medication use (an-
xiolytics, antidepressants and sedatives), years since transplant and 
current levels of psychological distress and QoL can predict FCR. In the 
first step, age, full- or part-time employment, currently taking psychotic 
medication and years since transplant were entered and significantly 
predicted FCR, F (4, 296) = 7.94, p < 0.001. Only current taking of 
psychotic medication and the number of years since transplant made a 
significant contribution to the prediction of FCR, explaining 3.6% and 
3.2% of the variance, respectively. The psychological distress score and 
the QoL total scores were entered in the second step and F change 
indicated a significant improvement in prediction over the use of the 
socio-demographic variables alone, F (6, 294) = 17.01, p < 0.001. 
Psychological distress and QoL made a significant contribution to the 
prediction of FCR explaining 1.1% and 5.4%, of the variance in FCR. 
After controlling for socio-demographic variables, higher levels of psy-
chological distress and lower QoL significantly predicted higher levels of 
FCR. These results also show that the number of years since transplant 
significantly predicted lower FCR and that age was positively related to 
increased FCR (Table 7). 
4. Discussion 
While numerous studies of cancer survivors have described high 
rates of FCR, little is known about its occurrence in survivors of allo-
geneic transplant for haematological malignancy. The results of this 
Table 4 
Screening for secondary malignancies and fear of cancer recurrence (FCR) post HSCT.  
Screening FCR Score Mean 
(sd) 
P value Early screening <2 
yrs 











Yes (n = 174) 12.98 (4.60) 0.24 Yes (n = 18) 15.78 (5.00) 0.69 Yes (n = 156) 12.66 (4.45) 0.32 
No (n = 177) 13.54 (4.32)  No (n = 32) 15.25 (4.29)  No (n = 145) 13.16 (4.24)  
Bowel cancer 
Yes (n = 116) 12.94 (3.95) 0.35 Yes (n = 13) 15.23 (3.10) 0.88 Yes (n = 103) 12.65 (3.88) 0.47 
No (n = 232) 13.42 (4.71)  No (n = 37) 15.46 (4.79)  No (n = 195) 13.03 (4.60)  
Pap smears (Females) 
Yes (n = 95) 12.05 (3.37) 0.003 Yes (n = 7) 13.00 (4.24) 0.04 Yes (n = 88) 11.98 (4.39) 0.07 
No (n = 53) 14.30 (4.41)  No (n = 11) 17.45 (3.96)  No (n = 42) 13.48 (4.19)  
Mammogram (Females) 
Yes (n = 77) 12.48 (4.00) 0.47 Yes (n = 6) 16.00 (6.26) 0.63 Yes (n = 71) 12.18 (3.66) 0.49 
No (n = 70) 13.01 (4.94)  No (n = 10) 14.80 (3.58)  No (n = 60) 12.72 (5.09)  
Prostate check (Males) 
Yes (n = 71) 13.84 (4.13) 0.38 Yes (n = 12) 15.75 (4.92) 0.60 Yes (n = 59) 13.46 (3.89) 0.49 
No (n = 129) 13.26 (4.60)  No (n = 20) 14.85 (4.50)  No (n = 109) 12.97 (4.58)   
Table 5 
Lifestyle choices, including complementary therapy use, and fear of cancer 
recurrence in long-term follow-up post HSCT.  
Life style factor FCR Score Mean (sd) P value 
Smoking 
Yes (n = 28) 12.68 (4.01) 0.50 
No (n = 327) 13.27 (4.50)  
Drinking alcohol 
Yes (n = 227) 12.92 (4.44) 0.10 
No (n = 128) 13.74 (4.46)  
Heavy alcohol* 
Yes (n = 27) 12.07 (3.33) 0.36 
No (n = 192) 12.91 (4.56)  
Exercise, sport 
Yes (n = 244) 12.93 (4.35) 0.06 
No (n = 109) 13.90 (4.59)  
Of those who Regular Exercise (at least 3x/week) 
Yes (161) 12.82 (4.41) 0.68 
No (77) 13.08 (4.33)  
Routine use of sunscreen 
Yes (n = 268) 13.41 (4.37) 0.21 
No (n = 78) 12.70 (4.57)  
Complementary therapy FCR Score Mean (sd) P value 
Nutrition &dietary approaches 
Yes (n = 45) 12.18 (4.83) 0.10 
No (n = 303) 13.35 (4.41)  
Herbal supplements 
Yes (n = 49) 12.96 (4.86) 0.65 
No (n = 295) 13.27 (4.37)  
Vitamin therapies 
Yes (n = 101) 13.27 (4.59) 0.97 
No (n = 239) 13.28 (4.44)  
Mind-body therapies 
Yes (n = 57) 12.81 (4.52) 0.42 
No(n = 286) 13.33 (4.46)  
Manipulative and body based therapies 
Yes (n = 91) 12.93 (4.52) 0.42 
No (n = 254) 13.37 (4.44)  
Traditional whole medicine systems 
Yes (n = 15) 12.53 (4.60) 0.55 
No (n = 327) 13.24 (4.45)  
Energy medicine 
Yes (n = 11) 12.18 (5.45) 0.44 
No (n = 332) 13.24 (4.41)  
Homeopathy 
Yes (n = 11) 11.90 (5.27) 0.32 
No(n = 329) 13.27 (4.43)  
** We also analysed the association between heavy alcohol use and FCR. Those 
with Heavy alcohol use did not demonstrate a significant association with FCR. 
The mean FCR scores in those with heavy alcohol use was higher than those 
reporting moderate/low alcohol consumption though this was not significant. 
The definition of heavy alcohol use was more than 2 standard drinks of alcohol 
per day (or >14/week). 
Table 6 
Intercorrelations between hierarchical regression variables.   
1 2 3 4 5 6 
1. FCR –      
2. Age .08 –     
3. Employed full or 
part time 
.16** .39*** –    
4. Psychotic 
medication 
.18*** -.03 .11 –   
5. Years since 
transplant 




.36*** -.02 .10 .26*** .04 – 
7. Quality of Life 
(Total FACT) 
-.43*** -.001 -.28*** -.30*** .04 -.66*** 
Note. *p < 0.05, **p < 0.01, ***p < 0.001. 
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study, which is the largest of its kind, make clear that many long-term 
survivors of allogeneic HSCT live with FCR; however, FCR diminishes 
as the time since diagnosis and treatment increases. This is an important 
finding for HSCT nurses, who often provide care for HSCT recipients for 
many years after transplant. This data is consistent with the results of 
previous cancer survivor studies (Deimling et al., 2006; Mehta et al., 
2003; Polinsky, 1994; Vickberg, 2003). 
Our results suggest that psychological distress (depression, anxiety 
and stress), mental health professional referral, pharmacological inter-
vention and lower QoL scores are all correlated with higher FCR scores. 
Whether these cause FCR or result from it is unclear. Researchers posit a 
bidirectional relationship between FCR and emotional distress, with 
psychological distress (anxiety, depression, stress) perpetuating FCR and 
FCR driving distress (Black and White, 2005). In this regard we found 
higher mean FCR scores in those taking antidepressants, anxiolytics and 
sedatives, in those referred to psychiatrists and, to a lesser extent, in 
those referred to a psychologist or social worker. Perhaps unsurpris-
ingly, and consistent with previous research, we found that QoL (as 
measured by the FACT-BMT) was also associated with FCR, with lower 
FCR in survivors reporting a higher QoL (Mehnert et al., 2013; Polinsky, 
1994; Simard et al., 2010; Thewes et al., 2012b). 
Given both the potential for relapse post HSCT and the higher inci-
dence of secondary malignancies in long-term survivors of HSCT we 
explored the associations between FCR, cancer screening adherence and 
relevant health behaviours in HSCT survivors. This is a complex issue as 
higher levels of FCR has been found to be positively associated with both 
hyper-vigilance and avoidance type behaviours with respect to health 
screening (Simard et al., 2010). In this study, no mean differences in FCR 
were found in those who had undergone several health screenings with 
the exception of women who did not report at least one PAP smear since 
transplant. This group of women were found to have a significantly 
higher mean FCR score. The paradoxical nature of the relationship be-
tween FCR and taking steps to diagnose it makes interpretation of this 
finding very difficult as while avoidance of screening may ameliorate 
psychological distress in the short term, in the long term, it may predict 
higher levels of FCR(Stanton et al., 2002). FCR did not appear to be 
associated with healthy lifestyle choices, exercise or the use of com-
plementary medicine. Importantly, the development of skin cancer 
post-HSCT was associated with a higher FCR, suggesting that a (new) 
cancer diagnosis post HSCT heightened survivor’s sensitivity to their 
underlying treatment related diagnosis and their FCR. 
In the regression analysis, younger age was negatively related to 
FCR. This finding is consistent with studies of other cancer populations 
that have reported a link between younger age and vulnerability to FCR 
(Simard and Savard, 2009). Exactly why younger survivors may be more 
likely to experience a FCR is unclear but may result from awareness of 
the greater ‘lifetime’ risk of cancer post-HSCT including the psycho-
logical and existential impact of a cancer diagnosis at a young age, and 
the greater family, financial and employment disruptions associated 
with cancer and HSCT in younger people (Gilroy et al., 2016; van de Wal 
et al., 2016). 
Intriguingly, while the majority of studies on FCR in cancer survivors 
have reported no relationship between FCR and employment, our results 
reveal a significant association between unemployment and higher FCR 
(Sarkar et al., 2014b). While we are unable to determine whether 
employment is causative in any way, in theory at least, returning to work 
or gaining work post- HSCT arguably may assist survivors regain a sense 
of meaning and normalcy, improve psychological well-being and 
distract survivors from thoughts associated with FCR (Peteet, 2000; 
Rasmussen and Elverdam, 2008). 
5. Limitations 
There are a number of limitations to this study that suggest caution in 
interpreting the results and generalising them to other populations or 
settings. First, because this is a cross sectional study it is not possible to 
ascertain the temporal association between FCR and other dynamic 
variables such as depression, anxiety and stress. Our study also reports 
data from survivors of allogeneic HSCT performed in one state in 
Australia, which may impact the generalizability of the results. Further, 
it is possible that some HSCT survivors may cope with FCR by engaging 
in avoidance, meaning that our results may underrepresent the inci-
dence of FCR because some of those most affected chose not to complete 
and return their survey. Finally, as we reported data from a single time- 
point in the lives of HSCT survivors, it is possible that for some, their 
current life experiences negated, or heightened, their experience of FCR. 
6. Conclusion 
The sequelae of allogeneic HSCT for haematological malignancies 
and the lingering threats of FCR can impair the QoL of HSCT survivors 
and is associated with significant adverse psychological impacts. For 
many patients with haematological malignancies who have undergone 
HSCT, returning to a fulfilling life following transplant relies, in part, on 
the patient’s ability to effectively manage FCR. Given the prevalence 
and impact of FCR in HSCT survivors and the lack of attention histori-
cally given to it by HSCT services and health professionals, we suggest 
that education and support programs pre- and post-allogeneic HSCT 
should provide information about the incidence, predictors and poten-
tial impact of FCR and the strategies that may be used to manage it. We 
believe HSCT nurses are best placed to assess for and provide this kind of 
service. And, just as importantly, post- HSCT follow-up should also 
include routine assessment of FCR in survivors so that health pro-
fessionals can advise them about the realistic likelihood of relapse, 
support them in dealing with FCR and encourage adherence with post- 
HSCT care, including screening for recurrence and secondary cancers. 
We believe this data is pivotal to HSCT nurses, as they are best placed to 
assess, and provide advice and support for HSCT survivors experiencing 
FCR. 
Table 7 
Hierarchical Multiple Regression of age, employment, psychotic medication, years since transplant, depression, anxiety and stress, and quality of life on fear of cancer 
recurrence (FCR).  
Variable Model 1 Model 2 
b SE sr2 95% CI b SE sr2 95% CI 
Age .03 .02 .003 − 0.01, 0.07 .05* .02 .013 0.01, 0.09 
Employed .11 .12 .004 − 0.12, 0.34 -.08 .11 .002 − 0.30, 0.13 
Psychotic medication 2.33*** .63 .036 1.09, 3.57 0.99 .60 .007 − 0.18, 2.17 
Years since transplant − 0.22** .07 .032 − 0.37, − 0.08 − 0.25*** .07 .035 − 0.38, − 0.12 
Depression, Anxiety, Stress (DASS 21)     .04** .01 .042 0.01, 0.06 
Quality of Life (Total FACT)     -.06*** .01 .019 − 0.09, − 0.03 
ΔR2     .16***    
R2 .10    .26    
Note. *p < 0.05, **p < 0.01, ***p < 0.001. 
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